Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 7/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 7/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.31 |
| ▸ | ARG2 | P78540 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6267731 | 0.96 | CYP2C19 (0.47) | TBXAS1CYP2C19CYP4F2CYP4A11CPB2 | |
| SCHEMBL2737133 | 0.91 | TBXAS1 (0.37) | TBXAS1CYP2C19CYP4F2CYP4A11CPB2 | |
| SCHEMBL6200581 | 0.89 | TBXAS1 (0.40) | TBXAS1CYP2C19CYP4F2CYP4A11CPB2 | |
| SCHEMBL798439 | 0.87 | TBXAS1 (0.50) | TBXAS1CYP2C19CYP4F2CYP4A11CPB2 | |
| SCHEMBL9181319 | 0.84 | CYP2C19 (0.56) | TBXAS1CYP2C19CYP4F2CYP4A11CPB2 | |
| SCHEMBL6272455 | 0.83 | CYP4F2 (0.37) | CYP4F2CYP4A11 | |
| SCHEMBL9182839 | 0.82 | CYP2C19 (0.60) | TBXAS1CYP2C19CYP4F2CYP4A11CPB2 | |
| SCHEMBL9182194 | 0.82 | TBXAS1 (0.54) | TBXAS1CYP2C19CYP4F2CYP4A11CPB2 | |
| SCHEMBL798202 | 0.82 | TBXAS1 (0.54) | TBXAS1CYP2C19CYP4F2CYP4A11CPB2 | |
| SCHEMBL9177447 | 0.82 | CYP2C19 (0.60) | TBXAS1CYP2C19CYP4F2CYP4A11CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0807627-B1 | Anilide compounds as ACAT inhibitors | KOWA CO (JP) | 2005-12-28 | — | — | EP | disclosed |
| US-6825223-B2 | ACYL COENZYME A CHOLESTEROL ACYLTRANSFERASE (ACAT) INHIBITORS; 2-SUBSTITUTED BENZIMIDAZOLE, BENZOXAZOLE, AND BENZOTHIAZOLES | KOWA COMPANY, LTD. (JP) | 2004-11-30 | — | — | US | disclosed |
| US-20020037910-A1 | Novel anilide compounds and pharmaceutical compositions comprising them | SHIBUYA KIMIYUKI (JP) | 2002-03-28 | — | — | US | disclosed |
| US-6204278-B1 | Anilide compounds, including use thereof in ACAT inhibitition | KOWA COMPANY, LTD. (JP) | 2001-03-20 | — | — | US | disclosed |
| EP-0807627-A2 | Anilide compounds as ACAT inhibitors | Kowa Company Ltd. (JP) | 1997-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037910-A1 | Novel anilide compounds and pharmaceutical compositions comprising them | ACAT1, LCAT, SOAT1 | TBXAS1 1571/4885CYP2C19 637/4885CYP4F2 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.